Naltrexone for Anxiety (SSO Trial)

Phase < 1

Waitlist Available

Led By Naomi Eisenberger, Ph.D.

Research Sponsored by University of California, Los Angeles

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 hours following the completion of the fear extinction procedure (during a follow-up fear reinstatement session).

Summary

This trial is testing whether the drug naltrexone eliminates the ability of social support figure reminders to help with fear extinction.

Who is the study for?

Healthy adults aged 18-35 with no history of mental illness or chronic physical conditions, not pregnant, and without liver disease. Participants must be fluent in English and comfortable swallowing pills. Those with a history of substance abuse or on certain medications are excluded.

What is being tested?

The study is testing if naltrexone blocks the positive effects of social support during fear extinction training. Half will receive naltrexone, half a placebo, before being exposed to cues associated with an electric shock alongside images of social support figures.

What are the potential side effects?

Naltrexone may cause nausea, headache, dizziness, anxiety, tiredness or trouble sleeping which could affect participants' response to fear extinction tasks.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ directly following a fear extinction procedure (during the experiment session).

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~directly following a fear extinction procedure (during the experiment session).

This trial's timeline: 3 weeks for screening, Varies for treatment, and directly following a fear extinction procedure (during the experiment session). for reporting.